Evidence map›Paper›PMID 40228023›Full record

ArticlePLoS biology2025

One-for-one or one-for-all? Considerations for filovirus vaccine development.

Andrea Marzi

Abstract read
In one paragraph

Article in PLoS biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. A Single-Dose Bundibugyo Virus Vaccine Protects Macaques Within 3 Days.bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Andrea MarziLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.ORCID https://orcid.org/0000-0003-0186-9587

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Filoviruses continue to re-emerge in Africa, causing localized public health emergencies. Although vaccination has slowly been implemented for Ebola virus, not for other filoviruses, holistic approaches are needed to broadly protect against filovirus threats.

Indexed as

FiloviridaeFiloviridae InfectionsVaccine DevelopmentViral VaccinesEbola VaccinesEbolavirusHemorrhagic Fever, EbolaHumansVaccinationEbola VaccinesViral Vaccines

Identifiers

PMID40228023
PMCPMC12021285

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.